47 related articles for article (PubMed ID: 18827334)
1. Development of adenoviral vectors that transduce Purkinje cells and other cerebellar cell-types in the cerebellum of a humanized mouse model.
Kul E; Okoroafor U; Dougherty A; Palkovic L; Li H; Valiño-Ramos P; Aberman L; Young SM
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101243. PubMed ID: 38605812
[TBL] [Abstract][Full Text] [Related]
2. Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.
Lewis TB; Glasgow JN; Harms AS; Standaert DG; Curiel DT
Viruses; 2014 Aug; 6(8):3293-310. PubMed ID: 25196484
[TBL] [Abstract][Full Text] [Related]
3. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1.
Mercier GT; Campbell JA; Chappell JD; Stehle T; Dermody TS; Barry MA
Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6188-93. PubMed ID: 15079060
[TBL] [Abstract][Full Text] [Related]
4. HDAd6/35++ - A new helper-dependent adenovirus vector platform for
Wang H; Georgakopoulou A; Zhang W; Kim J; Gil S; Ehrhardt A; Lieber A
Mol Ther Methods Clin Dev; 2023 Jun; 29():213-226. PubMed ID: 37081854
[TBL] [Abstract][Full Text] [Related]
5. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector.
Dakin RS; Parker AL; Delles C; Nicklin SA; Baker AH
Hum Gene Ther; 2015 May; 26(5):312-9. PubMed ID: 25760682
[TBL] [Abstract][Full Text] [Related]
6. Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.
Teigler JE; Kagan JC; Barouch DH
J Virol; 2014 Sep; 88(18):10354-63. PubMed ID: 24991003
[TBL] [Abstract][Full Text] [Related]
7. Current Use of Adenovirus Vectors and Their Production Methods.
Sayedahmed EE; Kumari R; Mittal SK
Methods Mol Biol; 2019; 1937():155-175. PubMed ID: 30706395
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity.
Hajeri PB; Sharma NS; Yamamoto M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526919
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.
Hulin-Curtis SL; Uusi-Kerttula H; Jones R; Hanna L; Chester JD; Parker AL
Cancer Gene Ther; 2016 Jul; 23(7):229-34. PubMed ID: 27229159
[TBL] [Abstract][Full Text] [Related]
10. Optimizing atoh1-induced vestibular hair cell regeneration.
Staecker H; Schlecker C; Kraft S; Praetorius M; Hsu C; Brough DE
Laryngoscope; 2014 Oct; 124 Suppl 5(Suppl 5):S1-S12. PubMed ID: 24938696
[TBL] [Abstract][Full Text] [Related]
11. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile.
White KM; Alba R; Parker AL; Wright AF; Bradshaw AC; Delles C; McDonald RA; Baker AH
J Cardiothorac Surg; 2013 Aug; 8():183. PubMed ID: 23937994
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the blood-testis barrier by coxsackievirus and adenovirus receptor.
Su L; Mruk DD; Cheng CY
Am J Physiol Cell Physiol; 2012 Oct; 303(8):C843-53. PubMed ID: 22875787
[TBL] [Abstract][Full Text] [Related]
13. Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.
Choi JH; Dekker J; Schafer SC; John J; Whitfill CE; Petty CS; Haddad EE; Croyle MA
Clin Vaccine Immunol; 2012 Jan; 19(1):84-95. PubMed ID: 22089246
[TBL] [Abstract][Full Text] [Related]
14. Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction.
Corjon S; Gonzalez G; Henning P; Grichine A; Lindholm L; Boulanger P; Fender P; Hong SS
PLoS One; 2011; 6(5):e18205. PubMed ID: 21637339
[TBL] [Abstract][Full Text] [Related]
15. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.
Lim ST; Airavaara M; Harvey BK
Pharmacol Res; 2010 Jan; 61(1):14-26. PubMed ID: 19840853
[TBL] [Abstract][Full Text] [Related]
16. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
Greig JA; Buckley SM; Waddington SN; Parker AL; Bhella D; Pink R; Rahim AA; Morita T; Nicklin SA; McVey JH; Baker AH
Mol Ther; 2009 Oct; 17(10):1683-91. PubMed ID: 19603000
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35.
Sakurai F
Biol Pharm Bull; 2008 Oct; 31(10):1819-25. PubMed ID: 18827334
[TBL] [Abstract][Full Text] [Related]
18. [Development of a replication-incompetent adenovirus vector derived from subgroup B adenovirus serotype 35].
Sakurai F
Yakugaku Zasshi; 2008 Dec; 128(12):1751-61. PubMed ID: 19043294
[TBL] [Abstract][Full Text] [Related]
19. [Characterization of adenovirus serotype 35 vectors using genetically modified animals and non-human primates].
Sakurai F; Kawabata K; Mizuguchi H
Yakugaku Zasshi; 2006 Nov; 126(11):1013-9. PubMed ID: 17077607
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
